Skip to main content

ATS INJUSTIS report finds home spirometry reliable in ILD

By October 18, 2021November 1st, 2021No Comments

Clinical Utility of Home versus Hospital Spirometry in Fibrotic ILD: Evaluation Following INJUSTIS Interim Analysis

Interim analysis of the It’s Not Just Idiopathic Pulmonary Fibrosis Study (INJUSTIS) shows that home spirometry performed via the patientMpower platform is feasible and reliable in patients with fibrotic interstitial lung disease (ILD). Home spirometry demonstrated a high level of agreement with hospital spirometry.

The data has just been published in the Annals of the American Thoracic Society , and we’ve provided a quick summary of key findings here.


Aim: Evaluate the clinical utility of home spirometry as an alternative to hospital spirometry in participants with fibrotic ILD.


  • 82 patients with fibrotic ILD (regardless of underlying aetiology or subtype)
  • Daily home spirometry, using patientMpower platform
  • Hospital spirometry at baseline and 3 months


  • Adherence to home spirometry (once/day) was 81% over 15 weeks. (This was despite results being blinded to  participants.)
  • High correlation between hospital and home spirometry FVC at baseline and 3 months
  • >90% of FVC home and clinic values were within agreement limits at baseline and 3 months
  • There was a tendency for home spirometry to underestimate FVC versus clinic measurement


Daily home spirometry in fibrotic ILD irrespective of aetiology or subtype, is feasible, reliable and within acceptable levels of agreement to hospital spirometry for clinical measurement. This is particularly relevant where clinical access or trial participation is limited due to geographical factors, patient choice, service pressures and future pandemics.